Insights into the immunopathogenesis of multiple sclerosis

Immunologic Research

Volumn 25, Issue 1, 2002, Pages 27-51

  Hellings, Niels ^a,b   Raus, Jef ^a,b   Stinissen, Piet ^a,b  

^a HASSELT UNIVERSITY   (Belgium)

^b Biomedical Research Institute   (Belgium)

Author keywords

Autoantigens; Immunotherapy; Multiple sclerosis; Myelin antigens; Myelin reactive T cells; T cell vaccination

Indexed keywords

ALTERED PEPTIDE LIGAND; AUTOANTIBODY; BETA INTERFERON; BETA1A INTERFERON; BLOCKING AGENT; CELL ADHESION MOLECULE; DNA VACCINE; GLATIRAMER; GROWTH FACTOR; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; MATRIX METALLOPROTEINASE INHIBITOR; MYELIN; MYELIN BASIC PROTEIN; PEPTIDE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; AUTOIMMUNE DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MALE; MULTIPLE SCLEROSIS; MYELIN SHEATH; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC DESENSITIZATION; T LYMPHOCYTE;

ANIMALS; AUTOANTIGENS; AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HLA-DR2 ANTIGEN; HUMANS; IMMUNOTHERAPY; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; MYELIN SHEATH; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; VACCINATION;

EID: 0036174787     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:25:1:27     Document Type: Review

References (200)

1. The epidemiology of multiple sclerosis: A general overview
2. Epidemiology of multiple sclerosis
3. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
4. On the immunopathology of plaque development and repair in multiple sclerosis
5. Pathology of the early lesion in multiple sclerosis
6. Multiple sclerosis: A pivotal role for the T cell in lesion development
7. Oligodendrocytes in the early course of multiple sclerosis
8. Parent-child concordance in multiple sclerosis
9. The natural history of multiple sclerosis: A geographically based study: 8: Familial multiple sclerosis
10. A population-based study of multiple sclerosis in twins
11. A population-based study of multiple sclerosis in twins: Update
12. Linkage analysis of HLA class II genes in Swedish multiplex families with multiple sclerosis
13. HLA class II-associated genetic susceptibility in multiple sclerosis: A critical evaluation
14. Novel HLA-DR2-related haplotypes in Hong Kong Chinese implicate the DQB1*0602 allele in susceptibility to multiple sclerosis
15. Multiple sclerosis: A modifying influence of HLA class I genes in an HLA class II associated autoimmune disease
16. A susceptibility locus for multiple sclerosis is linked to the T cell receptor beta chain complex
17. Polymorphic markers of human T-cell receptor alpha and beta genes. Family studies and comparison of frequencies in healthy individuals and patients with multiple sclerosis and myasthenia gravis
18. T-cell receptor V alpha and C alpha alleles associated with multiple and myasthenia gravis
19. HLA and T-cell receptor polymorphisms in Belgian multiple sclerosis patients: No evidence for disease association with the T-cell receptor
20. Germ-line polymorphism of TCR genes and disease susceptibility - Fact or hypothesis?
21. No association with germline T cell receptor beta-chain gene alleles or haplotypes in Swedish patients with multiple sclerosis
22. Genetic susceptibility to multiple sclerosis linked to myelin basic protein gene
23. Genetic susceptibility to multiple sclerosis may be linked to polymorphism of the myelin basic protein gene
24. Myelin basic protein gene polymorphism is not associated with chronic progressive multiple sclerosis
25. Genetic susceptibility in familial multiple sclerosis not linked to the myelin basic protein gene
26. Linkage analysis of candidate myelin genes in familial multiple sclerosis
27. Linkage and association analysis of genes encoding cytokines and myelin proteins in multiple sclerosis
28. Interleukin-10 (IL10) promoter polymorphisms and multiple sclerosis
29. Cytokines in genetic susceptibility to multiple sclerosis: A candidate gene approach
30. Intracellular adhesion molecule- 1 polymorphisms and genetic susceptibility to multiple sclerosis: Additional data and meta-analysis
31. Multiple sclerosis: The increased frequency of the ICAM-1 exon 6 gene point mutation genetic type K469
32. Susceptibility to multiple sclerosis associated with an immunoglobulin gamma 3 restriction fragment length polymorphism
33. Evaluation of the apo-1/Fas promoter mva I polymorphism in multiple sclerosis
34. A full genome search in multiple sclerosis
35. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22
36. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex
37. Epidemiologic evidence for multiple sclerosis as an infection
38. Epidemiology of multiple sclerosis: A critical overview
39. On the risk of multiple sclerosis according to age at immigration to South Africa
40. Virus-induced demyelination in man: Models for multiple sclerosis
41. Viruses and multiple sclerosis
42. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis
43. New perspectives in multiple sclerosis: Retroviral involvement and glial cell death
44. Gliotoxicity, reverse transcriptase activity and retroviral RNA in monocyte/macrophage culture supernatants from patients with multiple sclerosis
45. Detection of a gliotoxic activity in the cerebrospinal fluid from multiple sclerosis patients
46. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis
47. The association of the human herpesvirus-6 and MS
48. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA
49. Human herpesvirus 6 and multiple sclerosis: Survey of anti-HHV-6 antibodies by immunofluorescence analysis and of viral sequences by polymerase chain reaction
50. Absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients
51. Similar humoral and cellular immunological reactivities to human herpesvirus 6 in patients with multiple sclerosis and controls
52. Absence of seven human herpesviruses, including HHV-6, by polymerase chain reaction in CSF and blood from patients with multiple sclerosis and optic neuritis
53. Absence of HHV-6 and HHV-7 in cerebrospinal fluid in relapsing-remitting multiple sclerosis
54. An encephalitic episode in a multiple sclerosis patient with human herpesvirus 6 latent infection
55. Molecular evidences for a role of HSV-1 in multiple sclerosis clinical acute attack
56. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein
57. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading
58. Pathogenesis of multiple sclerosis - The immune diathesis and the role of viruses
59. In vivo labeling of blood T cells: Rapid traffic into cerebrospinal fluid in multiple sclerosis
60. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation
61. T-lymphocyte entry into the central nervous system
62. Lymphocyte homing and homeostasis
63. The central nervous system as an immunocompetent organ: Role of glial cells in antigen presentation
64. Peripheral blood gamma-delta T cells lyse fresh human brain-derived oligodendrocytes
65. The role of reactive oxygen species in the pathogenesis of multiple sclerosis
66. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls
67. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro
68. Cytokine-regulated proteases in autoimmune diseases
69. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
70. The T lymphocyte in experimental allergic encephalomyelitis
71. Experimental allergic encephalomyelitis and autoimmune disease
72. T cell necessity in the pathogenesis of experimental autoimmune encephalomyelitis in mice
73. Immunological aspects of demyelinating diseases
74. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis
75. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination
76. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones
77. Response of human T lymphocyte lines to myelin basic protein: Association of dominant epitopes with HLA class II restriction molecules
78. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis
79. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: Precursor frequency, fine specificity, and cytotoxicity
80. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis
81. Myelin autoreactivity in multiple sclerosis: Recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors
82. Increased frequency of interleukin 2-responsive T ceils specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis
83. Common T-cell receptor V beta usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis
84. Oligoclonal T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis
85. Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis
86. Homologies between T cell receptor junctional sequences unique to multiple sclerosis and T cells mediating experimental allergic encephalomyelitis
87. TCR repertoire to proteolipid protein (PLP) in multiple sclerosis (MS): Homologies between PLP-specific T cells and MS-associated T cellsin TCR junctional sequences
88. T cell receptor V alpha-V beta repertoire and cytokine gene expression in active multiple sclerosis lesions
89. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction
90. T cells responsive to myelin basic protein in patients with multiple sclerosis
91. HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides
92. T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis
93. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls
94. Interleukin-2 secreting cells in multiple sclerosis and controls
95. Clonal expansion of myelin basic protein-reactive T cells in patients with multiple sclerosis: Restricted T cell receptor V gene rearrangements and CDR3 sequence
96. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide
97. TCR usage in human and experimental demyelinating disease
98. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype
99. Interferon-gamma-induced oligodendrocyte cell death: Implications for the pathogenesis of multiple sclerosis
100. Tumor necrosis factor identified in multiple sclerosis brain
101. Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals
102. Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83-99)
103. The cellular and molecular events of central nervous system remyelination
104. The structure and function of central nervous system myelin
105. Three isoforms of human myelin basic protein: Purification and structure
106. Basis of microheterogeneity of myelin basic protein
107. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones
108. Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis
109. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis
110. T cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls
111. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation
112. Decreased dependence of myelin basic protein-reactive T cells on CD28- mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells
113. Minireview: Autoimmune responses to myelin proteolipid protein
114. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis
115. Identification of a second T cell epitope of human proteolipid protein (residues 89-106) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients
116. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans
117. Identification of a novel T cell epitope of human proteolipid protein (residues 40-60) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients
118. T cell response to two immunodominant proteolipid protein (PLP) peptides in multiple sclerosis patients and healthy controls
119. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis
120. Isolation and characterization of autoreactive proteolipid protein-peptide specific T-cell clones from multiple sclerosis patients
121. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein
122. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial giycoprotein, and 2′,3′-cyclic nucleotide 3′- phosphodiesterase in the CNS of adult rats
123. Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody
124. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system
125. Creation of a model for multiple sclerosis in Callithrix jacchus marmosets
126. Experimental allergic encephalomyelitis: The balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions
127. Demyelination induced in aggregating brain cellcultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein
128. Late complications of immune deviation therapy in a nonhuman primate
129. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein
130. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: Reactivity to the extracellular domain of MOG is directed against three main regions
131. Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis
132. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein
133. Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis
134. Cloning and expression of myelin-associated oligodendrocytic basic protein. A novel basic protein constituting the central nervous system myelin
135. Isolation and characterization of a novel oligodendrocyte-specific protein
136. Encephalitogenicity of myelin-associated oligodendrocytic basic protein and 2′,3′-cyclic nucleotide 3′-phosphodiesterase for BALB/c and SJL mice
137. T-cells specific for soluble recombinant oligodendrocyte-specific protein induce severe clinical experimental autoimmune encephalomyelitis in H-2(b) and H-2(s) mice
138. Encephalitogenic and neuritogenic T cell responses to the myelin- associated glycoprotein (MAG) in the Lewis rat
139. The T-lymphocyte response against myelin-associated glycoprotein and myelin basic protein in patients with multiple sclerosis
140. The central nervous system-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS)
141. Experimental autoimmune encephalomyelitis: The antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system
142. Multiple sclerosis: Comparison of the human T-cell response to S100 beta and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis
143. The small heat shock protein alpha B-crystallin as key autoantigen in multiple sclerosis
144. Presentation of alpha B-crystallin to T cells in active multiple sclerosis lesions: An early event following inflammatory demyelination
145. Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis
146. 2′,3′-cyclic nucleotide 3′-phosphodiesterase: A novel candidate autoantigen in demyelinating diseases
147. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis
148. Determinant spreading and the dynamics of the autoimmune T-cell repertoire
149. Predominant and stable T cell responses to regions of myelin basic protein can be detected in individual patients with multiple sclerosis
150. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: Epitope spreading versus clonal persistence
151. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone
152. Degeneracy in T-cell antigen recognition - Implications for the pathogenesis of autoimmune diseases
153. Activation and clonal expansion of human myelin basic protein-reactive T cells by bacterial superantigens
154. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease
155. The cognitive paradigm and the immunological homunculus
156. Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis
157. CDR1 T-cell receptor beta-chain peptide induces major histocompatibility complex class II-restricted T-T cell interactions
158. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein
159. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination
160. Treatments targeting the T cell receptor (TCR): Effects of TCR peptide-specific T cells on activation, migration, and encephalitogenicity of myelin basic protein-specific T cells
161. Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis
162. Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells
163. In vivo clonotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination
164. Cellular and Humoral Immune Responses Against Autoreactive T cells in Multiple Sclerosis Patients After T cell Vaccination
165. Gammadelta T cell responses to activated T cells in multiple sclerosis patients induced by T cell vaccination
166. The physiological role of regulatory T cells in the prevention of autoimmunity: The function of the thymus in the generation of the regulatory T cell subset
167. Peripheral autoantigen induces regulatory T cells that prevent autoimmunity
168. Suppressor cell function in multiple sclerosis: Correlation with clinical disease activity
169. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression
170. Autoimmunity can benefit self-maintenance
171. Autoimmune maintenance and neuroprotection of the central nervous system
172. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy
173. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury
174. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: Design and conduct of study and baseline characteristics of patients
175. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
176. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
177. Interferon-beta interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes
178. Interferon beta-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9
179. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis
180. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial
181. Copolymer-1-induced inhibition of antigen-specific T cell activation: Interference with antigen presentation
182. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses
183. Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: Pilot trial in multiple sclerosis
184. Myelin reactive T cells after T cell vaccination in multiple sclerosis: Cytokine profile and depletion by additional immunizations
185. Preliminary data of an extended openlabel phase I study of T cell vaccination in Multiple Sclerosis
186. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis
187. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides
188. Preferential T-cell receptor beta-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis
189. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6CDR2 peptide
190. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations
191. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity
192. Prevention of experimental autoimmune encephalomyelitis by MIP-1alpha and MCP-I naked DNA vaccines
193. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines
194. Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis
195. Immune tolerance mediated by recombinant proteolipid protein prevents experimental autoimmune encephalomyelitis
196. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: Modulation of T cell costimulation
197. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis
198. Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen
199. T cell design for therapy in autoimmune demyelinating disease
200. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells